Cara Therapeutics Cara (NASDAQ: CARA) Receives Priority Review Of NDA For KORSUVA Cara Therapeutics, Inc. [NASDAQ: CARA] and Vifor Pharma disclosed Monday that US FDA has recognized and awarded Priority Review for the NDA for KORSUVA solution for the cure of mild-to-serious pruritus in hemodialysis sufferers.
CARA Patience Might Pay Off With Stocks Like Cara Therapeutics, Inc. (CARA) Cara Therapeutics, Inc. (CARA) has seen some recent action in the stock market and its stock finished trading at $13.26 yesterday. People are starting to take notice of CARA as the stock traded as high as $13.58 and as low as $13.
